Actinogen Medical share price crashes 67% lower on Alzheimer's study results

The Actinogen Medical Ltd (ASX:ACW) share price has been one of the worst performers on the ASX with a 67% decline today. Here's why…

One of the worst performers on the Australian share market on Tuesday has been the Actinogen Medical Ltd (ASX: ACW) share price.

In morning trade the Alzheimer's-focused drug development company's shares are down 67% to 1.6 cents.

a woman

Why has the Actinogen Medical share price crashed lower today?

Investors have been hitting the sell button this morning after Actinogen Medical released the results of its XanADu phase II clinical trial of 10mg Xanamem in patients with mild dementia due to Alzheimer's disease.

According to the release, the XanADu trial established that a 10mg daily dose of Xanamem is safe and has the ability to effectively inhibit cortisol production, as demonstrated by the expected increase in related hormones, including adrenocorticotropic hormone (ACTH).

However, it did not demonstrate adequate efficacy in improving cognition in mild Alzheimer's disease. Disappointingly, the primary and secondary endpoint measures did not demonstrate statistical differences between Xanamem 10mg and placebo.

What now?

It isn't necessarily the end of the road just yet. Management advised that further analysis of the trial data is underway in the hope of exploring trends that could identify any specific cognitive domains in which positive trends may be evident.

It also suggested that higher doses of Xanamem and longer treatment durations may be necessary to effectively demonstrate its potential to improve cognition in Alzheimer's disease.

Studies using 20mg and 30mg doses are underway and results are expected to be announced by the end of June. After which, management will use the data to refine Xanamem's ongoing clinical development program.

Despite the disappointing results, the company's CEO, Dr Bill Ketelbey, was encouraged by the trial.

He said: "These XanADu results are certainly encouraging. While 10mg Xanamem was not shown to be a clinically effective dose in Alzheimer's disease, the safety and pharmacodynamic effects observed show potential that higher doses and a longer treatment duration of Xanamem may be efficacious."

Also in the news today in the pharmaceutical industry is Mayne Pharma Group Ltd (ASX: MYX). The Mayne Pharma share price has dropped 1% lower after analysts at UBS held firm with their neutral rating but cut the price target on its shares to 73 cents after revising down margins for its generics segment.

Elsewhere, the CSL Limited (ASX: CSL) share price has pushed 1% higher despite there being no news out of the biotech giant.

James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Fallers

Codan share price A dismayed kid dressed as a scientist stands with his back to a rocket crashed into the ground
Share Fallers

Xero shares crash to a 7-year low after a brutal sell-off

The decline has wiped out years of share price gains.

Read more »

Two miners at a mine site on their tablets, with mining machinery behind them.
Share Fallers

Why has the Mineral Resources share price fallen 12% this week?

It’s been another tough week for Mineral Resources shareholders.

Read more »

A man holds his hand to his chin with a furrowed brow, making an expression of puzzlement or confusion.
Share Fallers

Top 3 ASX 200 shares now below their 200-day moving average

Are these businesses still a buy?

Read more »

A young man clasps his hand to his head with a pained expression on his face and a laptop in front of him.
Share Fallers

What are the most shorted ASX shares on the market right now?

Two names, two opposite bear cases.

Read more »

An arrow crashes through the ground as a businessman watches on.
Share Fallers

Warning: Corporate Travel shares have crashed 80%. What on earth just happened?

An 80% crash has left investors asking what went so wrong.

Read more »

Stressed businessman sits in panic amid digital stock market financial background.
Share Fallers

The five worst-performing ASX 200 shares in August unmasked

Investors sent these five ASX shares crashing 17% to 23% in August. But why?

Read more »

Stressed businessman sits in panic amid digital stock market financial background.
Share Fallers

Why Megaport, Lendlease and JB Hi-Fi shares all crashed 14% to 15% this week

ASX investors punished Lendlease, Megaport, and JB Hi-Fi this week. But why?

Read more »

Woman checking out new laptops.
Consumer Staples & Discretionary Shares

Down 14% today: Are JB Hi-Fi shares now a bargain-bin buy?

Could JB's plunge mean a bargain buy?

Read more »